Conduent to Report Second-Quarter 2025 Financial Results on August 6, 2025
The call will be available by live audiocast along with the news release and online presentation slides at https://investor.conduent.com.
The conference call will also be available by calling 877-407-4019 toll free. If requested, the conference ID is 13754400.
The international dial-in is +1 201-689-8337. The international conference ID is also 13754400.
A recording of the conference call will be available by calling 877-660-6853 three hours after the conference call concludes. The access ID for the recording is 13754400.
The call recording will be available until Aug. 20, 2025.
We look forward to your participation.
About Conduent
Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent's solutions and services digitally transform its clients' operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients' missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Top analyst warns on MicroStrategy results ahead of earnings
Top analyst warns on MicroStrategy results ahead of earnings originally appeared on TheStreet. Strategy (Nasdaq: MSTR), formerly MicroStrategy, is expected to report its financial results for the second quarter of 2025 after market hours on July 31. Strategy is the largest public corporate holder of Bitcoin. The company's Bitcoin stack of 628,791 coins is currently worth more than $74 billion. The firm's executive chairman and co-founder Michael Saylor urged anyone interested in Strategy or Bitcoin to join the earnings call at 5:00 p.m. EST. Zacks, the investment research firm, said it expected the Bitcoin treasury firm to report $112.15 million in Q2 revenue, hoping for a 0.64% rise year over year (YoY). Zacks expected Strategy's earnings per share (EPS) to record a loss of $0.12 per share. There are several factors, such as the Donald Trump administration's announcement to establish a strategic Bitcoin reserve, more regulatory clarity, Bitcoin's recent rally, and institutional and corporate adoption of the king coin, that go in favor of Strategy, the analysis mentioned. However, it added, "Bitcoin's inherent volatility, along with Strategy's stretched valuation, makes the MSTR stock a risky bet ahead of the second quarter of 2025."Let's look at the company's performance in Q1 2025. Strategy recorded a total revenue of $111.1 million, a decline of 3.6% YoY. In Q1, it reported a gross profit of $77.1 million, operating expenses of $6 billion, and loss from operations of $5.921 billion. As of March 31, it had cash and cash equivalents of $60.3 million. The MSTR stock, which closed at $395.04 on July 30, has grown more than 35% year-to-date (YTD). In contrast, Bitcoin, trading at $118,315.66 at press time, has only grown 25% YTD. Clearly, the leading Bitcoin treasury firm has outpaced Bitcoin itself — at least in YTD timeframe. Top analyst warns on MicroStrategy results ahead of earnings first appeared on TheStreet on Jul 31, 2025 This story was originally reported by TheStreet on Jul 31, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial
We recently compiled a list of CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company developing bladder-sparing immunotherapies, with a primary focus on cretostimogene grenadenorepvec, a targeted oncolytic virus therapy for bladder cancer. Their lead program targets high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), an area with limited options beyond invasive surgery. Recent data from the Phase 3 BOND-003 trial, presented in June 2025, revealed a 75.5% complete response rate, with 42.3% of patients maintaining that response at 24 months. Impressively, 97.3% remained free of progression to muscle-invasive disease, and 91.6% avoided cystectomy. The therapy was also well-tolerated, with no grade 3 or higher treatment-related adverse events reported. Cretostimogene stands out as a potential new standard for NMIBC, offering durable cancer control without surgery and preserving patients' quality of life. Its promising results have sparked interest in combining it with other therapies like pembrolizumab, further expanding its therapeutic potential. A healthcare specialist in the laboratory testing an Oncology-related product. CG Oncology, Inc. (NASDAQ:CGON) continues to expand its clinical footprint with trials targeting both BCG-naïve and previously treated patients. A Biologics License Application (BLA) is expected soon, supported by strong Phase 2 combination data published in Nature Medicine. The business is also offering expanded access programs, broadening patient reach before full regulatory approval. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
17 minutes ago
- Yahoo
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal
We recently compiled a list of Arrowhead Pharmaceuticals, Inc. stands seventh on our list. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs. Its proprietary TRiM platform enables precise silencing of disease-causing genes, positioning the company as a frontrunner in gene-targeted treatments and one of the best growth stocks in the biotech space. In July 2025, the company achieved a major milestone, a $100 million payment from Sarepta Therapeutics as part of a broader licensing and collaboration deal. The agreement includes clinical and preclinical RNAi candidates, offering the corporation up to $10 billion in potential milestone and royalty payments. This collaboration provides strong financial backing and external validation of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)'s RNAi technology. The business is making significant progress in the late-stage development of its cardiometabolic pipeline. In July 2025, the company initiated the Phase 3 YOSEMITE study for zodasiran in homozygous familial hypercholesterolemia. It also completed enrollment for several Phase 3 trials (SHASTA-3, SHASTA-4, and MUIR-3) evaluating plozasiran for severe hypertriglyceridemia and rare lipid disorders. Plozasiran's NDA has been accepted by the FDA, with a potential approval date of November 18, 2025. A biotechnologist in a lab setting, examining a sample of liquid for research and development. These developments underscore Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)'s momentum in bringing RNAi therapies to market. Positive Phase 3 results, including significant reductions in triglycerides and pancreatitis, highlight the strong efficacy of its treatments. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
